Clinical application of washed red blood cells in perioperative patients with liver cancer / 中国输血杂志

【Objective】 To estimate the application value of washed red blood cells (RBC) in perioperative patients with liver cancer. 【Methods】 86 perioperative patients with liver cancer who met the inclusion/exclusion criteria were divided into observation group (n=42) and control group (n=44). In the observation group, 22 patients were transfused with RBC and 20 with washed RBC. Patients without RBC transfusion worked as the controls. The name of disease, tumor stage, tumor size, Hb before and after blood transfusion, transfusion volume and blood components, adverse reaction to blood transfusion, operation time and blood loss during surgery, systemic infection, tumor recurrence and metastasis, and survival time were recorded. Blood transfusion efficacy, survival time, adverse reaction to blood transfusion, tumor recurrence and metastasis among these groups were compared. 【Results】 Among the non-transfusion group, washed RBC group and RBC group, the Hb(g/L)were 93.9±16.5 vs 80.4±24.5 vs 74.7±26.1, operative time (h) 2.8±0.7 vs 4.3±1.6 vs 3.9±2.0, operative blood loss(mL) 291.0±0.3 vs 388.0±165.8 vs 466.3±198.4 respectively before blood transfusion (all P0.05). There were significant differences in tumor metastasis (50% vs 43%) and recurrence (50% vs 43.1%) between blood transfusion group and non-blood transfusion group (P0.05). The nosocomial infection rate in washed RBC group (36%) was significantly lower that that in RBC group (88.6%) and non-transfusion group (50%) (P<0.05). 【Conclusion】 Blood transfusion caused by hypoxia may increase tumor metastasis and recurrence in perioperative patients with liver cancer. Transfusion of washed RBC can achieve the curative effect and reduce adverse reactions to blood transfusion, but has no significant impact on the survival time.

Progress in the expressions of programmed death 1 and programmed death ligand 1 in lung cancer / 肿瘤研究与临床

In tumor immunotherapy, the study of programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) provides a new approach for the comprehensive treatment of advanced lung cancer. About 20％ of patients with non-small cell lung cancer could benefit from lung cancer immunotherapy, while those with high PD-L1 expression will benefit more. At present, there are few related studies on PD-1 expression at home and abroad, and the detection of PD-1/PD-L1 expressions is mostly concentrated in tumor tissues. With the research progress of liquid biopsy technology, the convenience and accuracy of peripheral blood testing are also receiving more and more attention. However, there are still few biological indicators for predicting the efficacy of tumor immunotherapy, and the uniform standard and accuracy of testing still need more clinical practice and exploration. This article reviews the research on the expressions of PD-1 and PD-L1 in tissues and peripheral blood of patients with lung cancer, aiming to provide reference for the treatment of lung cancer with immune checkpoint blockers.

Effect of chemotherapy on the expression of CD8 + CD28-T cells in peripheral blood of non-small-cell lung cancer patients / 国际肿瘤学杂志

Objective To observe the expression of CD8 + CD28-T cells in the peripheral blood of non-small-cell lung cancer (NSCLC) patients,and to investigate the effect of chemotherapy on CD8 + CD28-T cells expression and its clinical significance.Methods Flow cytometry was used to evaluate the level of CD8 + CD28-T cells in peripheral blood of 70 untreated NSCLC patients and 60 healthy controls.The association between CD8 + CD28-T cells and the clinical features was analyzed.We also investigated the changes of CD8 + CD28-T cells in 30 NSCLC patients who received chemotherapy by GP (gemcitabine,cisplatin) and NP (navelbine,cisplatin).Results The proportion of CD8 + CD28-T cells in lung cancer group was significantly higher than that in healthy group (59.003％ ± 15.329％ vs.41.036％ ± 15.435％,t =35.904,P =0.001).No correlation was found between CD8 + CD28-T cells expression and the gender (F =1.374,P =0.697),pathological pattern (F =0.779,P =0.509) and clinical stage (F =0.070,P =0.933).But CD8 + CD28-T cells expression was correlated with the age (F =15.038,P =0.001).The level of CD8 + CD28-T cells after NP chemotherapy was lower than that before chemotherapy (55.293％ ± 14.637％ vs.58.793％ ± 12.510％,t =2.017,P =0.044).And the level of CD8 + CD28-T cells after GP chemotherapy was lower than that before chemotherapy (54.127％ ± 13.924％ vs.60.700％ ± 16.401％,t =3.007,P =0.009).Conclusion CD8 + CD28-T cells express highly in NSCLC patients peripheral blood.Chemotherapy down-regulates CD8 + CD28-T cells expression,which provides a new reference for combination with chemotherapy and immunotherapy in NSCLC patients.

Expression and clinical significance of CD+8 CD-28 and CD+4CDhigh25 CDlow127 regulatory T cells in peripheral blood of lung cancer patients / 肿瘤研究与临床

Objective To observe the changes of CD+8CD+28,CD+8CD-28 and CD+4CDhigh25CDlow127 regulate T (Treg)cellsin peripheral blood of lung cancer patients,and to analyze the correlation between CD+8CD-28 and CD+4CDhigh25CDlow127 Treg cells to reveal the role and clinical significance of them in lung cancer patients.Methods Flow cytometry was applied to evaluate the level of CD+8CD+28,CD+8CD-28 and CD+4CDhigh25CDlow127 Treg cells in peripheral blood of 60 untreated lung cancer patients and 60 healthy controls group.The association of each term with clinical features was analyzed.Results The percentage of CD+8CD-28 and CD+4CDhigh25CDlow127 Treg cells in lung cancer group[(58.430:15.749) ％,(7.365±2.025) ％]was significantly higher than those in healthy group [(41.057±15.436)％,(6.648±1.669)％,(t=6.102,P＜0.05;t=2.115,P＜0.05)],while the percentage of CD+8CD+28cells is lower(41.570±15.739)％ than that in healthy group[(58.700±15.298)％,(t=-6.043,P＜0.05)].No close associations were found between three index and gender,age,and biological characteristics.With the increase of TNM stage,The percentage of CD+4CDhigh25 CDlow127 Treg cells increased gradually,which was remarkably higher in patients rith stage Ⅳ than that with stage ⅢA(t=-3.898,P＜0.05).The percentage of CD+4CDhigh25 CDlow127 Tregcells was uncorrelated with CD+8CD-28 cells(r=-0.169,P＞0.05).Conclusion The higher percentage of CD+8CD-28 and CD+4CDhigh25 CDlow127 Treg cells,the lower percentage of CD+8CD+28 cells may be the important reasons of immune suppression in lung cancer patients.Though there is no correlation between CD+8CD-28 and CD+4CDhigh25 CDlow127 Treg cells,it is may be helpful to understand immunologic function and it may look for more specific therapy and provide a new reference in the prognosis of lung cancer.